Janux Therapeutics Promotes Zachariah McIver to Chief Medical Officer-February 2024-www.financetom.com

Janux Therapeutics Promotes Zachariah McIver to Chief Medical Officer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Janux Therapeutics Promotes Zachariah McIver to Chief Medical Officer

Jan 24, 2025 1:43 PM

04:18 PM EST, 01/24/2025 (MT Newswires) -- Janux Therapeutics ( JANX ) said Friday it promoted Zachariah McIver to chief medical officer.

McIver was previously the executive medical director at Amgen ( AMGN ) for more than four years, the biopharmaceutical company said.

Previous page： NuVista Energy Reduces Production Guidance After Unscheduled Third-Party Downtime Next page： LiveOne Says Collaboration With Tesla Surpassed 350,000 Paid Subscribers

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

NuVista Energy Reduces Production Guidance After Unscheduled Third-Party Downtime

Dec 18, 2024

08:32 AM EST, 12/18/2024 (MT Newswires) -- NuVista Energy ( NUVSF ) on Wednesday reduced its production guidance for the fourth quarter due to an unscheduled downtime at a third-party gas plant. The company said it temporarily curtailed production in the greater Wapiti area following the disruption impacting its production volumes in December. As a result, NuVista lowered its production...

LiveOne Says Collaboration With Tesla Surpassed 350,000 Paid Subscribers

Dec 18, 2024

08:30 AM EST, 12/18/2024 (MT Newswires) -- LiveOne ( LVO ) said Wednesday its multiyear collaboration with Tesla (TSLA) reached 350,000 paid subscribers as of Dec. 15. ...

Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

Dec 18, 2024

08:31 AM EST, 12/18/2024 (MT Newswires) -- Corvus Pharmaceuticals ( CRVS ) said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a favorable safety and efficacy profile. The company said that patients receiving soquelitinib showed a 55.9% reduction in the Eczema Area and Severity...

HBT Financial Board Approves up to $15 Million Share Buyback Plan

Dec 18, 2024

08:30 AM EST, 12/18/2024 (MT Newswires) -- HBT Financial ( HBT ) said Wednesday its board approved an up to $15 million share buyback plan, to take effect after its current plan expires Jan. 1. The new buyback plan will be in effect until Jan. 1, 2026, the company said. Shares of the company were down 1.6% in recent Wednesday...